Manganese-based nanoparticles plus gambogic acid targeted hypoxic tumor microenvironment by enhancing ROS generation and provided antitumor treatment and improved immunotherapy DOI Creative Commons

Zixin Liang,

Xinyi Xu, Ning Wang

et al.

RSC Advances, Journal Year: 2025, Volume and Issue: 15(15), P. 11283 - 11292

Published: Jan. 1, 2025

Colorectal cancer (CRC) remains a major global health challenge, particularly in advanced stages where drug resistance leads to high recurrence rates and poor survival outcomes. This study investigates novel therapeutic approach combining gambogic acid (GA) with manganese dioxide (MnO2) nanoparticles (MBG NPs) enhance anti-tumor efficacy the acidic hypoxic tumor microenvironment (TME). The development of MBG NPs involved conjugating MnO2 nanosheets bovine serum albumin (BSA) for effective GA encapsulation, optimizing delivery both components. We explored potential Mn2+ ions released from synergize alleviate hypoxia modulate TME, thereby improving immune response. In vitro assays demonstrated significant cytotoxicity against mouse colon cells (CT26 cells), enhanced apoptosis elevated reactive oxygen species (ROS) levels. vivo studies using BALB/c mice showed that treatment significantly reduced volumes improved compared controls. Additionally, combined programmed death-1 inhibitor (aPD-1) further augmented effects. Histological analyses confirmed necrosis changes TME composition, indicating this synergistic strategy overcome microsatellite stable (MSS) CRC, inhibit growth benefit patient survival. These findings highlight promising application nanoparticle-based platforms enhancing immunotherapy outcomes colorectal cancer.

Language: Английский

Manganese-based nanoparticles plus gambogic acid targeted hypoxic tumor microenvironment by enhancing ROS generation and provided antitumor treatment and improved immunotherapy DOI Creative Commons

Zixin Liang,

Xinyi Xu, Ning Wang

et al.

RSC Advances, Journal Year: 2025, Volume and Issue: 15(15), P. 11283 - 11292

Published: Jan. 1, 2025

Colorectal cancer (CRC) remains a major global health challenge, particularly in advanced stages where drug resistance leads to high recurrence rates and poor survival outcomes. This study investigates novel therapeutic approach combining gambogic acid (GA) with manganese dioxide (MnO2) nanoparticles (MBG NPs) enhance anti-tumor efficacy the acidic hypoxic tumor microenvironment (TME). The development of MBG NPs involved conjugating MnO2 nanosheets bovine serum albumin (BSA) for effective GA encapsulation, optimizing delivery both components. We explored potential Mn2+ ions released from synergize alleviate hypoxia modulate TME, thereby improving immune response. In vitro assays demonstrated significant cytotoxicity against mouse colon cells (CT26 cells), enhanced apoptosis elevated reactive oxygen species (ROS) levels. vivo studies using BALB/c mice showed that treatment significantly reduced volumes improved compared controls. Additionally, combined programmed death-1 inhibitor (aPD-1) further augmented effects. Histological analyses confirmed necrosis changes TME composition, indicating this synergistic strategy overcome microsatellite stable (MSS) CRC, inhibit growth benefit patient survival. These findings highlight promising application nanoparticle-based platforms enhancing immunotherapy outcomes colorectal cancer.

Language: Английский

Citations

0